PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced United States Patent and Trademark Office (USPTO) has issued Patent No. 11,771,707 related to its micro-suspension platform technology.
Patent No. 11,771,707 provides additional protection for SX600 and complements previously issued U.S. Patent Nos. 8,927,529, 9,572,771, 10,350,222, 10,925,883, and 11,058,692. The newly granted ‘707’ patent underscores SpineThera’s ongoing dedication to developing novel medical technologies that enhance spinal health and improve patients' quality of life. The invention covered by this patent is a result of years of research and development by SpineThera’s team of skilled scientists, engineers, and medical professionals.
“Our lead asset, SX600, is built on our micro-suspension platform technology, which is clinically proven to provide sustained-release of the active pharmaceutical ingredient for 90 days. This 6th US Patent provides additional depth and breadth to our patent portfolio covering our micro-suspension technology. We will continue to vigorously pursue development of SX600 with the aim of offering patients a non-opioid treatment for chronic sciatica pain,” said Jeff Missling, CEO of SpineThera.
Recently SpineThera announced successful market research results for its lead asset SX600 showing a potential 70% adoption rate by physicians to treat patients suffering with lumbar radicular pain (sciatica). “This news, paired with strong clinical trial results in the phase-2 SALIENT trial, leads us to believe SX600 holds great potential to be a more effective sciatica pain management option for patients, and a leading drug in the non-opioid category,” Missling said.
About SpineThera
SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained-release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.
SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk profile compared to current epidural steroid injections for radicular leg pain. SpineThera is based in Medical Alley, Minnesota, the global epicenter of health innovation and care.
